Safety, tolerability, and impact on allergic inflammation of autologous E.coli autovaccine in the treatment of house dust mite asthma - a prospective open clinical trial

BMC Complementary and Alternative Medicine

Stefan Zielen¹  Johannes Schulze¹  Ralf Schubert¹  Bianca Weigand¹  Markus A Rose¹ 

[1] Dpt. of Allergy, Pulmonology, and Cystic Fibrosis, Children's and Adolescents' Hospital, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany

关键词: asthma;    house dust mite allergy;    tolerability;    safety;    autovaccine;   

Others  :  1233627
DOI  :  10.1186/1472-6882-11-45

 received in 2010-06-23, accepted in 2011-06-03,  发布年份 2011

【 摘 要 】

Background

Asthma is increasing worldwide and results from a complex immunological interaction between genetic susceptibility and environmental factors. Autovaccination with E. coli induces a strong TH-1 immune response, thus offering an option for the treatment of allergic diseases.

Methods

Prospective open trial on safety, tolerability, and impact on allergic inflammation of an autologous E.coli autovaccine in intermittent or mild persistent house dust mite asthma. Determination of exhaled nitric monoxide (eNO) before and after bronchial mite challenge initially and after nine months of autovaccination.

Results

In nine subjects and a total of 306 injections, we observed 101 episodes of local erythema (33.3%; median of maximal diameter 2.5 cm), 95 episodes of local swelling (31.1%; median of maximal diameter 3 cm), and 27 episodes of local pain (8.8%). Four subjects reported itching at the injection site with a total of 30 episodes (9.8%). Median eNO increase after autovaccination was significantly smaller (from 27.3 to 33.8 ppb; p = 0.334) compared to initial values (from 32.6 to 42.2 ppb; p = 0.046) (p = 0.034). We observed no serious adverse events. All organ functions (inclusive electrocardiogramm) and laboratory testing of the blood (clinical chemistry, hematology) and the urine (screening test, Β-microglobuline) were within normal limits. Vital signs undulated within the physiological variability.

Conclusion

The administration of autologous autovacine for the treatment of house dust mite asthma resulted in a reduction of the eNO increase upon bronchial mite challenge. In nine subjects and 306 injections, only a few mild local reactions and no systemic severe adverse events were observed.

Trial registration

EudraCT Nr. 2005-005534-12

ClinicalTrials.gov ID NCT00677209

【 授权许可】

   
2011 Rose et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Berezhnaia NM, Beiko VA, Evseeva TA: Immunological mechanisms of specific hyposensitization in allergic diseases of an infectious nature. IV. The comparative characteristics of the changes in the immunological processes in nonspecific (dekaris) and specific (autovaccine) immunotherapy of infectious-allergic bronchial asthma. Zh Mikrobiol Epidemiol Immunobiol 1982, 12:95-9.
• [2]Abramson MJ, Puy RM, Weiner JM: Allergen immunotherapy for asthma. Cochrane Review, The Cochrane Library; 2004.
• [3]Martin M, Michalek SM, Katz J: Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immunity 2003, 71(5):2498-507.
• [4]Halasa J: Justification of treatment with autovaccine. Med Dosw Mikrobiol 1994, 46(1-2 Suppl):5-9.
• [5]Wilczynski K, Kozminska J, Bilisnki A: The testing of auto-vaccination of probands with chronic purulent otitis media. Otolaryngol Pol 1995, 49(Suppl 23):183.
• [6]Zaluga E: Skin reactions to antigens of propionibacterium acnes in patients with acne vulgaris treated with autovaccine. Ann Acad Med Stetin 1998, 44:65-85.
• [7]Okrasinska-Cholewa B: Clinical evaluation of treating accessory nasal sinus diseases in children using autovaccine. Med Dosw Mikrobiol 1994, 46(1-2 Suppl):67-73.
• [8]Rubisz-Brzezinska J, Wilkczyk R, Brzezinska l: Clinical evaluation of serious forms of acne treated with autovacine. Med Doszw Microbiol 1994, 46(1-2 Suppl):35.
• [9]Filatov VF, Filatov SV: Polypous ethmoiditis. Vestn Otorinolaringol 1999, 2:11-4.
• [10]Novotny Z, Krupicka J, Hanova I, et al.: Treatment with autovaccines and the immunologic profile of patients. Cesk Otolaryngol 1990, 39(1):40-7.
• [11]Nolte O, Morscher J, Weiss HE, et al.: Autovaccination of dairy cows to treat post partum metritis caused by Actinomyces pyogenes. Vaccine 2001, 19(23-24):3146-53.
• [12]Rusch V, Ottendorfer D, Zimmermann K, et al.: Open uncontrolled pilot trial on the immunomodulatory potential of autovaccine. Arzneim Forsch 2001, 51:690-97.
• [13]American Thoracic Society: Recommendations for standardized procedures for the online and offline measurements of exhaled lower respiratory nitric oxide and nasal oxide in adults and children. Am J Resp Crit Care Med 1999, 160:2104-17.
• [14]Zielinski T, Zimmermann K, Ottendorfer D, et al.: Quality control and documentation of efffectiveness of bacterial autovaccines with the use of flow cytometry. Arzneim Forsch 1998, 48:502.
• [15]Wright AE, Douglas SR: On the action exerted upon the Staphylococcus pyogenes by human body fluids and an elaboration of protective elements in the human organism in response to inoculation of a Staphylococcus vaccine. Proc Roy Soc Lond 1904, 74:147.
• [16]Halasa J, Halasa M: Significance of immunotherapy in treatment of bronchial asthma. Pol Merkuriusz Lek 2002, 12(68):140-2.
• [17]Kay PM: Costimulation and the regulation of antimicrobial immunity. Immunol Today 1995, 16:423.
• [18]Renz H: Autovaccine reduced bronchial hypersensitization in ovalbumin sensitized mice. University of Marburg, Dpt. of Clinical Immunology. Personal communication; 2010.
• [19]Schubert R, Kitz R, Beermann C, et al.: Effect of n-3 Polyunsaturated Fatty Acids in Asthma after low dose Allergen Challenge. Int Arch Allergy Immunol 2009, 148(4):321-329.
• [20]Drachenberg KJ, Wheeler AW, Stuebner P, et al.: A well tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56:498-505.
• [21]Kleine-Tebbe J, Fuchs Th, Klimek L, et al.: Specific immunotherapy with allergens. Allergologie 2001, 24(11):535-44.